FDA Panel Votes on Maribavir for Post-Transplant CMV Infection
The Food and Drug Administration (FDA)’s Antimicrobial Drugs Advisory Committee voted unanimously to recommend the use of maribavir for the treatment of refractory cytomegalovirus (CMV) infection and disease with or without genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.
FDA Panel Votes on Maribavir for Post-Transplant CMV Infection – MPR (empr.com)
